"could leronlimab have hastened or stopped metastasis that was most certainly the reason he died?"
Even if James Van Der Beek had very low (or none) CCR5 expression, Leronlimab would not have hastened his metastases. It just would not have helped. However, it was likely that he had elevated CCR5 expression. In that case, Leronlimab would have either reduced or stopped his circulating tumor cells. Additionally, it would have taken control of the tumor microenvironment, and reprogrammed the macrophages, reduced angiogenesis, and (possibly) raised the PD-1 expression. Furthermore, Leronlimab would have returned his immune functions to homeostasis, reducing the trauma that his body was experiencing. Leronlimab would decrease the traumatic effects of any adjunctive treatments on the non-cancerous cells. In other words, Leronlimab would have been effective treatment if he displayed elevated CCR5 expression.
Personally, I believe that future cancer treatments will begin with Leronlimab, modulating the immune response, as the basic building block for the treatment protocol. Perhaps it would be beneficial to administer Leronlimab for a few weeks. Then, based on the patient's biomarkers, create a more effective, personalized, protocol with adjunctive treatments.
Just my layman's opinions.
Even if James Van Der Beek had very low (or none) CCR5 expression, Leronlimab would not have hastened his metastases. It just would not have helped. However, it was likely that he had elevated CCR5 expression. In that case, Leronlimab would have either reduced or stopped his circulating tumor cells. Additionally, it would have taken control of the tumor microenvironment, and reprogrammed the macrophages, reduced angiogenesis, and (possibly) raised the PD-1 expression. Furthermore, Leronlimab would have returned his immune functions to homeostasis, reducing the trauma that his body was experiencing. Leronlimab would decrease the traumatic effects of any adjunctive treatments on the non-cancerous cells. In other words, Leronlimab would have been effective treatment if he displayed elevated CCR5 expression.
Personally, I believe that future cancer treatments will begin with Leronlimab, modulating the immune response, as the basic building block for the treatment protocol. Perhaps it would be beneficial to administer Leronlimab for a few weeks. Then, based on the patient's biomarkers, create a more effective, personalized, protocol with adjunctive treatments.
Just my layman's opinions.
9
